TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19769010

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Boomers
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Skipping medications
Number of subjects: 386
Study: 17680222

Group type: EXPERIMENTAL
Intervention: Pulsed-dose-rate (PDR) brachytherapy, prescribed reference dose of 49.8 Gy in 83 fractions of 0.6 Gy every hour, total treatment time 3-4 days.
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy, prescribed reference dose of 32 Gy in eight fractions of 4 Gy, twice daily.
Number of subjects: 105
Study: 15197804

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 8/4 mg
Number of subjects: 773

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 773
Study: 11224833

Group type: EXPERIMENTAL
Intervention: MnCC vaccine (4 doses at 2, 4, 6 months)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MnCC vaccine (after Dose 3)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MnCC vaccine (after Dose 4)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MnCC vaccine (after three doses)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MnCC vaccine (after booster)
Number of subjects: 106

Group type: COMPARATOR
Intervention: 7-valent conjugate pneumococcal vaccine (control)
Number of subjects: 106
Study: 9679571

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical esophagectomy
Number of subjects: 0
Study: 7994879

Group type: EXPERIMENTAL
Intervention: Goserelin depot (3.6 mg) administered monthly for 6 months (n = 22)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Goserelin depot (3.6 mg) administered monthly for 12 months (n = 8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Goserelin depot (3.6 mg) administered for 3 months
Number of subjects: 30
Study: 2532434

Group type: EXPERIMENTAL
Intervention: Adaptation to the climate of moderate altitudes (2100 m above sea level) for 24 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Exposure to salt mine microclimate (Chon-Tuz) for 170 hours (days 5-23)
Number of subjects: 25
Study: 973959

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg t.d.s. for 5 days)
Number of subjects: 0
Study: 31092647

Group type: EXPERIMENTAL
Intervention: TAU with PCOMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 0
Study: 30423641

Group type: EXPERIMENTAL
Intervention: Wallis implant after lumbar discectomy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Discectomy alone
Number of subjects: 77
Study: 25183203

Group type: EXPERIMENTAL
Intervention: Invited-to-screening arm
Number of subjects: 5852

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 5852

Group type: EXPERIMENTAL
Intervention: Screening attendees with positive findings
Number of subjects: 5852
Study: 23865402

Group type: EXPERIMENTAL
Intervention: Metacognitive beliefs measured using the MCQ-30
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Perceived uncontrollability and danger of thinking (metacognitive belief)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Beliefs about voices measured using the BAVQ-R
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory-II and Beck Anxiety Inventory
Number of subjects: 77
Study: 21500885

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral analysis system of psychotherapy (CBASP) plus pharmacotherapy
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Brief supportive psychotherapy (BSP) plus pharmacotherapy
Number of subjects: 491

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Change in social problem solving
Number of subjects: 491
Study: 19062268

Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2766

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (toremifene or tamoxifen)
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Chemo-endocrine therapy (CMF or AC plus toremifene or tamoxifen)
Number of subjects: 2766
Study: 17409581

Group type: EXPERIMENTAL
Intervention: Electrophysiologic study (EPS)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Standard therapy for heart failure
Number of subjects: 474
Study: 15064583

Group type: EXPERIMENTAL
Intervention: Resistance training (RTR) 3 times a week for 12 weeks, using three sets of six to eight repetitions at 85-90% 1-RM on lower-body exercises
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CON) performed no resistance training
Number of subjects: 22
Study: 11464037

Group type: EXPERIMENTAL
Intervention: 3 mg apomorphine SL
Number of subjects: 296

Group type: COMPARATOR
Intervention: 4 mg apomorphine SL
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 9732078

Group type: EXPERIMENTAL
Intervention: Force-monitoring platform
Number of subjects: 3

Group type: COMPARATOR
Intervention: Bathroom scale
Number of subjects: 3

Group type: COMPARATOR
Intervention: Against a therapist's hand
Number of subjects: 3
Study: 8089245

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) rinses, 15 ml, 2 times daily for 1 month
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo solution rinses
Number of subjects: 23
Study: 3385044

Group type: EXPERIMENTAL
Intervention: Indomethacin therapy (double-blind, controlled, crossover trial in 14 patients)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 44
Study: 28736268

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 145
Study: 26871270

Group type: EXPERIMENTAL
Intervention: Otelixizumab
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 24666558

Group type: EXPERIMENTAL
Intervention: Individualized training group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-individualized training group
Number of subjects: 61
Study: 22940511

Group type: EXPERIMENTAL
Intervention: Home‐based individualized exercise program (HBIEP)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 187
Study: 20193794

Group type: COMPARATOR
Intervention: CPVA (Circumferential Pulmonary Vein Ablation) group, n = 73
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: CPVA-CM (Circumferential Pulmonary Vein Ablation with Circular Mapping catheter) group, n = 73
Number of subjects: 146
Study: 18390799

Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.i.d.)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Higher-dose oral contraceptive pill (OCP) (35 microg ethinyl estradiol/2 mg cyproterone acetate)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control subjects (17 weight-matched)
Number of subjects: 38
Study: 15531357

Group type: EXPERIMENTAL
Intervention: Non-consensual kiss condition (audiotape description)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Consensual kiss condition (audiotape description)
Number of subjects: 121
Study: 12464458

Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink (TFD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control drink containing tryptophan
Number of subjects: 8
Study: 10631438

Group type: EXPERIMENTAL
Intervention: Propofol 1% (n = 7)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propofol 2% (n = 9)
Number of subjects: 16
Study: 7577204

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide, cisplatin, and carmustine with autologous bone marrow support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose cyclophosphamide, cisplatin, and carmustine
Number of subjects: 0
Study: 1663851

Group type: EXPERIMENTAL
Intervention: Therapy for back pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retest at one‐to‐two week intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health status instruments
Number of subjects: 0
Study: 7214801

Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium methyl-glucamine diatrizoate (ionic medium)
Number of subjects: 16
Study: 30367541

Group type: EXPERIMENTAL
Intervention: Bifocal glasses
Number of subjects: 119

Group type: COMPARATOR
Intervention: Unifocal glasses
Number of subjects: 119
Study: 28421317

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS) - 250 ml of Arginaid Water ingested in the evening before the experiment and at 7:00 am on the day of the experiment.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group - fasting after dinner and drinking only water until 7:00 am on the day of the experiment.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS) - 250 ml of Arginaid Water.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group - fasting and drinking only water.
Number of subjects: 14
Study: 26556021

Group type: EXPERIMENTAL
Intervention: Tension band wiring (TBW)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hook plate (HP)
Number of subjects: 80
Study: 23480975

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 26
Study: 21219660

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 mcg and albuterol 400 mcg
Number of subjects: 5783

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5783
Study: 19395131

Group type: EXPERIMENTAL
Intervention: Isohumulones 32 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Isohumulones 48 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Isohumulones 16 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 17948074

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g on the night before surgery and 1 g twice daily for 5 days after surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no ascorbic acid)
Number of subjects: 100
Study: 15711820

Group type: EXPERIMENTAL
Intervention: Synbiotics (postoperative enteral feeding including synbiotics)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (enteral feeding only)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 12202015

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg qd plus sertraline 50 mg qd
Number of subjects: 13

Group type: COMPARATOR
Intervention: Naltrexone 50 mg qd with placebo
Number of subjects: 13
Study: 9818688

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GM-CSF (5 microg/kg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both G-CSF and GM-CSF
Number of subjects: 26
Study: 8580921

Group type: EXPERIMENTAL
Intervention: Topical retinoic acid (n = 32)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 54
Study: 2653593

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no prior exercise)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 24 h postexercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: 48 h postexercise
Number of subjects: 6
Study: 76166

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg at bedtime)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30272538

Group type: EXPERIMENTAL
Intervention: GMT+WMT
Number of subjects: 18

Group type: COMPARATOR
Intervention: WMT
Number of subjects: 18
Study: 30939922

Group type: EXPERIMENTAL
Intervention: Automated hovering intervention with patient-level incentives for daily weight monitoring and diuretic adherence, combined with automated feedback into the clinical care pathway.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 0
Study: 29335840

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary access
Number of subjects: 174

Group type: COMPARATOR
Intervention: Subclavian approach
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary access (when subclavian failed)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Lead complications
Number of subjects: 174
Study: 27817819

Group type: EXPERIMENTAL
Intervention: FF 100 μg OD
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: FP 100 μg BD
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: FP 250 μg BD
Number of subjects: 371

Group type: COMPARATOR
Intervention: FF/VI 100/25 μg OD
Number of subjects: 371

Group type: COMPARATOR
Intervention: Withdrawal due to worsening asthma
Number of subjects: 371

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 371
Study: 24809261

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (NMBA) - vecuronium, loading dose of 0.1 mg/kg, continuous infusion of 0.05 mg/kg/h for 24-48 hours
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no NMBA treatment)
Number of subjects: 96
Study: 22713257

Group type: EXPERIMENTAL
Intervention: Home-based HIV counselling and testing (HBHCT) programme
Number of subjects: 2964
Study: 19318295

Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine patch
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 220
Study: 17311621

Group type: EXPERIMENTAL
Intervention: Viusid (three sachets daily) + IFN alpha‐2b (5 MU on alternate days) + ribavirin (13 mg/kg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: IFN alpha‐2b (5 MU on alternate days) + ribavirin (13 mg/kg daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Viusid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Without Viusid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy (without Viusid)
Number of subjects: 100
Study: 15500398

Group type: EXPERIMENTAL
Intervention: Oxypurinol added to standard therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 11174617

Group type: EXPERIMENTAL
Intervention: Early indomethacin treatment (3 x 0.2 mg/kg every 12 hours, starting on day 3)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Early indomethacin treatment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Late indomethacin treatment (starting on day 7)
Number of subjects: 127
Study: 9747547

Group type: EXPERIMENTAL
Intervention: Intervention GPs (received the intervention)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control GPs (did not receive the intervention)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intervention GPs (47% complied with the intervention)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Legibility and doctor's assessment determination
Number of subjects: 150
Study: 8111598

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges (DBPCFC)
Number of subjects: 320
Study: 3387686

Group type: EXPERIMENTAL
Intervention: Dipyridamole 100 mg and acetylcysteine 100 mg every 6 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Acetylcysteine 100 mg every 6 h
Number of subjects: 8
Study: 30720579

Group type: EXPERIMENTAL
Intervention: TN at ST36
Number of subjects: 18

Group type: COMPARATOR
Intervention: TN at PTN
Number of subjects: 18
Study: 30106531

Group type: EXPERIMENTAL
Intervention: High frequency sonic power toothbrush (A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oscillating-rotating power toothbrush (B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional sonic toothbrush (C)
Number of subjects: 120
Study: 28150367

Group type: EXPERIMENTAL
Intervention: 2.5% benzoyl peroxide gel
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel
Number of subjects: 458
Study: 25535265

Group type: EXPERIMENTAL
Intervention: Brief relationship abuse education and counseling intervention
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Standard-of-care control condition
Number of subjects: 1011
Study: 23247716

Group type: EXPERIMENTAL
Intervention: Gradient of 8%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Increasing gradient
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Uphill cycling
Number of subjects: 18
Study: 21620906

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18465329

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 1000
Study: 16572117

Group type: EXPERIMENTAL
Intervention: Dopamine (2 mug/kg min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15071246

Group type: EXPERIMENTAL
Intervention: Bachmann's Bundle pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right atrial appendage pacing
Number of subjects: 0
Study: 15670701

Group type: EXPERIMENTAL
Intervention: Recognition of prosodic expressions of emotions using fMRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonetic monitoring of emotional tone stimuli using fMRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of activation maps between emotional tone recognition and phonetic monitoring
Number of subjects: 0
Study: 10628612

Group type: EXPERIMENTAL
Intervention: Opti‐Q from Abbott
Number of subjects: 44

Group type: COMPARATOR
Intervention: IntelliCath from Baxter
Number of subjects: 44
Study: 7495202

Group type: EXPERIMENTAL
Intervention: Copper T 380A (TCU 380A)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Multiload copper 375 (MLCU 375)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Multiload copper 250 (MLCU 250)
Number of subjects: 3
Study: 2143890

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous (i.v.) administration
Number of subjects: 0
Study: 7285484

Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine 15 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine 25 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (0 mg d-amphetamine)
Number of subjects: 8
Study: 30744571

Group type: EXPERIMENTAL
Intervention: Education and self-management intervention
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Headache classification interview
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Recruitment from primary care
Number of subjects: 18
Study: 28488178

Group type: EXPERIMENTAL
Intervention: Ultrathin colonoscope (UTC)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Pediatric colonoscope
Number of subjects: 270
Study: 25351237

Group type: EXPERIMENTAL
Intervention: 0.5 µg/kg DEX in 10 mL isotonic saline (group II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.0 µg/kg DEX in 10 mL isotonic saline (group III)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 10 mL isotonic saline (group I)
Number of subjects: 90
Study: 23551935

Group type: EXPERIMENTAL
Intervention: Tolvaptan 7.5 mg/day
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 21464680

Group type: EXPERIMENTAL
Intervention: 2 counseling callbacks
Number of subjects: 1923

Group type: COMPARATOR
Intervention: 4 counseling callbacks
Number of subjects: 1923
Study: 19587624

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 81

Group type: COMPARATOR
Intervention: Loss of resistance (LOR)
Number of subjects: 81
Study: 17021811

Group type: EXPERIMENTAL
Intervention: Continued thiamazole medication (11.0+/‐7.0 mg/day)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Discontinuation of thiamazole for 2 days
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Discontinuation of thiamazole for 1 day
Number of subjects: 316
Study: 15148204

Group type: EXPERIMENTAL
Intervention: Single piece SA30AL IOL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Three piece MA30BA IOL
Number of subjects: 20
Study: 11534564

Group type: EXPERIMENTAL
Intervention: 30‐min steady state test
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 5‐min steady state test
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry with 5‐min steady state test
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Time required for 5‐min steady state data collection
Number of subjects: 62
Study: 9780135

Group type: EXPERIMENTAL
Intervention: Intravenous cocaine administration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine administration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Smoked cocaine administration
Number of subjects: 6
Study: 7825033

Group type: EXPERIMENTAL
Intervention: PBMC co-cultivated with phytohemagglutinin‐P activated PBMC from healthy, HIV‐1 antibody negative donors
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PBMC from individuals with concomitant p24 antigenemia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Culture positive, p24 antigenemic patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: p24 serum negative cases with CD4+ counts of < 500 cells/mm3
Number of subjects: 36
Study: 29288250

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (250,000 or 500,000 IU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25531677

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control (oral glucose-lowering drugs excluding TZD)
Number of subjects: 587
Study: 24045120

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) needle
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional (BRK-1) needle
Number of subjects: 72
Study: 21327593

Group type: EXPERIMENTAL
Intervention: Repeated pulse therapy of methylprednisolone (1 g for 3 days) and cyclophosphamide (15 mg/kg per day for 2 days), followed by dexamethasone (5 mg every 6 hours) until PaO2 >80 mmHg or repeated 1 g MP for 3 days and 1 g CP for 1 day if PaO2 <60 mmHg
Number of subjects: 111

Group type: COMPARATOR
Intervention: High doses of cyclophosphamide (2 mg/kg per day) and dexamethasone (5 mg every 6 hours) for 14 days
Number of subjects: 111